Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Source: Globenewswire
Clinical Findings on Nebokitug: Recent analyses from the Phase 2 SPRING trial indicate that treatment with nebokitug leads to significant, dose-dependent improvements in inflammatory and fibrotic biomarkers in patients with primary sclerosing cholangitis (PSC), supporting its potential as a first-in-class therapy for PSC and other fibro-inflammatory diseases.
Pharmacokinetic Insights: Data presented at EASL 2025 show effective antibody-target engagement of nebokitug with its CCL24 target, demonstrating dose-proportional increases in drug concentration and corresponding decreases in relevant disease biomarkers, reinforcing its therapeutic efficacy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
